SystImmune Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Jie D’Elia, Ph.D., MBA, as its new Chief Executive Officer. Experience With a career spanning over two decades in the biopharmaceutical industry, D’Elia most recently served as Senior Vice President for business development in oncology, hematology, and cell therap...